Feature | Radiation Oncology | October 04, 2016 | By Michael V. Knopp, M.D., Ph.D., Chadwick L. Wright, M.D., Ph.D., Katherine Binzel, Ph.D. and Jun Zhang, Ph.D.

Precision PET Imaging to Advance Personalized Cancer Management

New cPET and dPET technologies and methodologies will contribute to the goals of precision medicine and will further expand the clinical utilization of PET

PET imaging
PET imaging

Precision medicine is not only a buzzword, it is a call to action to radically advance our capabilities in the era of molecular targeted medicine. Positron emission tomography (PET) has firmly established its leading role as a capable oncologic molecular imaging technique over the last two decades, however its technological advances have been modest at best.

An essential capability of a methodology to support precision medicine with the goal of being tailored to the individual patient and disease characteristics is that such a methodology is a valid biomarker and ideally enables consistent and accurate quantitative readouts. This is an area where PET imaging has been challenged and limited not due to inherent inabilities, but more due to technological limitations. 

 

Technological Challenges

In the days of bragging rights on how many megapixels one’s smartphone has, PET imaging has been lagging behind other cross-sectional imaging methodologies in its ability to improve the precision of the detector chain and the resulting image quality. While computed tomography (CT) imaging is done routinely at cross-sectional image matrixes of 512 x 512, PET imaging has remained nearly unchanged over the last two decades at matrix sizes of 144 x 144 to 200 x 200. This fact gives an insight into some of the technological challenges of conventional PET (cPET) technology. 

Another challenge for PET has been the lack of harmonization in acquisition procedures, post-processing and semi- or even quantitative assessment approaches. While considerable progress has been made based on best practices and regulatory and scientific recommendations, variabilities are still largely jeopardizing the robust evolution of PET as a noninvasive, molecular-based technique to enable precision medicine. 

 

Opportunities

Today, radiomics and big data are emerging and highly visible efforts that require precise, high-quality imaging to deliver on this promise of personalized medicine. These big imaging data opportunities are being further nurtured by the availability of decentralized and increasingly cloud-based computational capabilities. Another increasingly important opportunity for PET is its role as a companion diagnostic in the area of tissue markers or genetic profile-driven therapies, as well as its evolving role into integrated theranostic approaches. With such promising and exciting prospects, the introduction and clinical integration of new technologies can drive new PET imaging paradigms.

An essential and increasingly accepted PET technology advance has been the refinement of time-of-flight (TOF). This helps to reduce the uncertainty of the true three-dimensional location of the PET isotope annihilation event and thus more precisely localize radiotracer uptake within the body. Current TOF cPET systems can now be improved through the introduction of higher definition reconstructions from the standard definition (SD) PET imaging which uses image matrix sizes of up to 200 x 200, to high definition (HD) of up to 400 x 400, thus reducing the reconstructed cPET image voxel volumes from ~64 mm3 to ~8 mm3. Figure 1 presents a whole-body FDG cPET image using the default SD reconstruction and the new HD reconstruction of the same dataset. The image comparison highlights a visually sharper HD image that has less partial volume effect and more accurate quantification and contributes to improved overall imaging precision.

The backbone of cPET has been photomultiplier tube-based detector technology that requires Anger logic to appropriately detect and localize the coincident annihilation photons. This is then processed using analog signal technologies. A recent technical advance that was predominately driven to enable clinical PET/MR was the introduction of solid-state, silicon-based photomultipliers with analog signal processing technologies. The most recent advance is the introduction of solid-state, digital photon counting (DPC) PET detectors and the replacement of analog signal processing, which enables a fully integrated digital detection and processing chain with markedly improved TOF timing resolution.

Our team is conducting pre-clinical and clinical trials using a pre-commercial release fully DPC-based PET (dPET) system that consistently provides 325 ps TOF timing resolution (Vereos Digital PET/CT, Philips). It also enables even higher-definition imaging using reconstruction voxel sizes of 1 mm3 with an ultra high-definition (UHD) reconstruction approach. Figure 2 presents an intra-individual comparison of a FDG whole-body PET scan performed back to back between a SD cPET and an UHD dPET. 

 

Expanding Clinical Utilization

The current observations in the ongoing clinical trials with cPET and dPET already indicate that these new technologies and methodologies will significantly contribute to the goals of precision medicine and will further expand the clinical utilization of PET to be a clinically even more useful biomarker to guide the management of personalized oncologic therapies.

 

Michael V. Knopp, M.D., Ph.D., coordinating author, is professor of radiology and Novartis chair of imaging research, principal investigator and director, Wright Center of Innovation in Biomedical Imaging and the Ohio Imaging Research and Innovation Network. He is also vice chair of research for the Department of Radiology at The Ohio State University Wexner Medical Center.

Related Content

Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
IBA Gathers Experts on Flash Irradiation During ASTRO
News | Proton Therapy | September 17, 2019
IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019...
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

The PlanCheck module now part of SunCheck, automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent.

News | Quality Assurance (QA) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, running Sept. 15-18 in Chicago, Sun Nuclear...
Varian Unveils Ethos Solution for Adaptive Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning

The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning. Image courtesy of Siemens Healthineers.

News | Computed Tomography (CT) | September 15, 2019
Siemens Healthineers debuted two computed tomography (CT) systems dedicated to radiation therapy (RT) planning at the...
Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the...
Akesis Galaxy SRS System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | September 13, 2019
The Akesis Galaxy, a gamma stereotactic radiosurgery system (SRS) with continuous 360-degree rotational technology, has...
Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019
News | Radiation Oncology | September 13, 2019
Philips will showcase its integrated radiation oncology portfolio at the American Society of Radiation Oncology (ASTRO...